T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that management will present virtually at the following upcoming webinar and healthcare conference:

On April 16, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, reported that management will present virtually at the following upcoming webinar and healthcare conference (Press release, T-Cure Bioscience, APR 16, 2021, View Source [SID1234580486]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Beacon Targeted Therapies’ Cell Therapies-Frontiers in Solid Tumor Treatment

Gang Zeng, Chief Executive Officer, will participate the fireside panel discussion on Tuesday, April 20, 2021 at 12:00 p.m. (EDT). Dr. Zeng will cover general topics of adoptive cell therapy, including opportunities to overcome current challenges in treating solid tumors.
TCR-based Therapies Summit

Erika von Euw, Senior Director of Translational Research, will lead a workshop on Tuesday, June 8, at 9:30 a.m. (EDT), titled "Development of Novel TCRs Derived from Responding Patients."
Gang Zeng, will give a presentation on Tuesday, June 8, at 3:00 p.m. (EDT), titled "Leveraging the Insights Gained from TIL Therapy to Improve Solid Tumor Immunotherapy".